Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Blood (2018) 132 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2018-99-113284

Published: 2018

Journal Articles

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Blood (2018) 132 (Supplement 1): 124.

https://doi.org/10.1182/blood-2018-99-112899

Published: 2018

Journal Articles

The Combination of 41BB and CD28 Costimulatory Signals Endows Lower Affinity CAR T Cells with the Most Optimal Properties for Selective Targeting of the Tumor Associated Antigen CD38

Esther Drent, MSc, Renée Poels, BSc, Niels WCJ Van De Donk, Sonja Zweegman, MD PhD, Henk M Lokhorst, Richard WJ Groen, PhD, Tuna Mutis, PhD, Maria Themeli, MD PhD

Blood (2017) 130 (Supplement 1): 3183.

https://doi.org/10.1182/blood.V130.Suppl_1.3183.3183

Published: 2017

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius

Saad Z Usmani, MD, Hareth Nahi, Brendan M Weiss, MD, Nizar J. Bahlis, MD, Andrew Belch, Henk M Lokhorst, Peter M. Voorhees, MD, Paul G Richardson, MD, Clarissa Uhlar, Jianping Wang, Ming Qi, Sagar Lonial, MD

Blood (2017) 130 (Supplement 1): 3107.

https://doi.org/10.1182/blood.V130.Suppl_1.3107.3107

Published: 2017

Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Blood (2017) 130 (Supplement 1): 3124.

https://doi.org/10.1182/blood.V130.Suppl_1.3124.3124

Published: 2017

Journal Articles

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, MD PhD, Marie José Kersten, MD, Edo Vellenga, MD, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Monique C Minnema, Sarah Lonergan, Antonio Palumbo, MD, Henk M Lokhorst, Annemiek Broyl, MD PhD, Karim Saad Iskander, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3141.

https://doi.org/10.1182/blood.V130.Suppl_1.3141.3141

Published: 2017

Journal Articles

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Hilma J van der Horst, Marije B Overdijk, Esther CW Breij, Martine Chamuleau, MD PhD, Henk M Lokhorst, Tuna Mutis, PhD

Blood (2017) 130 (Supplement 1): 1835.

https://doi.org/10.1182/blood.V130.Suppl_1.1835.1835

Published: 2017

Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 838.

https://doi.org/10.1182/blood.V130.Suppl_1.838.838

Published: 2017

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

Esther Drent, MSc, Maria Themeli, MD PhD, Renée Poels, Niels W.C.J. van de Donk, MD PhD, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD

Blood (2016) 128 (22): 2170.

https://doi.org/10.1182/blood.V128.22.2170.2170

Published: 2016

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood (2016) 128 (14): 1821–1828.

https://doi.org/10.1182/blood-2016-07-726729

Published: 2016

Includes: Supplemental data

Journal Articles

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E. Axel, Khaja Syed, Richard W. J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W. C. J. van de Donk

Blood (2016) 128 (7): 959–970.

https://doi.org/10.1182/blood-2016-03-703439

Published: 2016

Includes: Supplemental data

Journal Articles

Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W. C. J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser

Blood (2016) 128 (3): 384–394.

https://doi.org/10.1182/blood-2015-12-687749

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa M. Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

Blood (2016) 128 (1): 37–44.

https://doi.org/10.1182/blood-2016-03-705210

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

Niels W. C. J. van de Donk, Philippe Moreau, Torben Plesner, Antonio Palumbo, Francesca Gay, Jacob P. Laubach, Fabio Malavasi, Hervé Avet-Loiseau, Maria-Victoria Mateos, Pieter Sonneveld, Henk M. Lokhorst, Paul G. Richardson

Blood (2016) 127 (6): 681–695.

https://doi.org/10.1182/blood-2015-10-646810

Published: 2016

NARROW

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

The Combination of 41BB and CD28 Costimulatory Signals Endows Lower Affinity CAR T Cells with the Most Optimal Properties for Selective Targeting of the Tumor Associated Antigen CD38

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only